PDSB News and Press, PDS Biotechnology Corporation From 10/05/22

FLORHAM PARK, N.J., Oct. 05, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that two abstracts reporting the result...

Summary Today we put PDS Biotechnology in the spotlight for the first time. The company got positive news from the FDA this week and is advancing its primary drug candidate across multiple indications. An investment analysis follows in the paragraphs below. The i...

PDS Biotechnology ( NASDAQ: PDSB ), a biopharma focused on cancer immunotherapies, added 13% pre-market Monday after the company announced that a recent End-of-Phase 2 meeting with the FDA brought clarity to the late-stage development of its lead asset PDS0101. At the ...

FLORHAM PARK, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that it has successfully completed an End-o...

FLORHAM PARK, N.J., Sept. 23, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced PDS Biotech granted nonstatutory stock opt...

FLORHAM PARK, N.J., Sept. 22, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that Dr. Frank Bedu-Addo, President and Ch...

FLORHAM PARK, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that checkpoint inhibitor (CPI) refractory...

FLORHAM PARK, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune ...

PDS Biotechnology Corp. ( NASDAQ: PDSB ) has filed for a $150 mixed shelf offering . The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for development and commercialization...

Initial tranche of $25 million provides funding in preparation for registrational trial for lead candidate PDS0101 Conference call scheduled for Thursday, August 25, 2022 at 8:00 AM EDT FLORHAM PARK, N.J., Aug. 24, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (...